Assurance de qualité pour le cancer rectal – phase 2 ...

More documents

Recommendations

Info

156 PROCARE – phase 2 KCE reports 81Proportion of stage II-III patients treated with neoadjuvant5-FU based chemoradiation, that received a continuousinfusion of 5-FUProportion of stage II-III patients treated with a longcourse of preoperative pelvic RT or chemoradiation, thatcompleted this neoadjuvant treatment within the plannedtimingProportion of stage II-III patients treated with a longcourse of preoperative pelvic RT or chemoradiation, thatwas operated 6 to 8 weeks after completion of the(chemo)radiationRate of acute grade 4 radio(chemo)therapy-relatedcomplicationsBavaria Burgundy North NL SW SPAIN UK DK NNo Not used No No No No No NoNo No No Yes No No No NoNo Yes No * Yes Yes No No YesNo No No No No No No NoPatients treated with local excision or TEMS by stage/level No Yes Yes Yes Yes Yes Yes YesProportion of R0 resections per stage/level No Yes Yes Yes Yes No Yes YesProportion of APR and Hartmann’s procedures perNo Yes Yes Yes Yes Yes Yes Yesstage/levelProportion of patients undergoing sphincter-sparingNo Yes No Yes Yes Yes No Nosurgery with/without temporary stoma at primarysurgery, still having their stoma 1y after surgeryRate of patients with major leakage of the anastomosis No No limited Yes Yes Yes Yesafter SSOInpatient or 30-day mortality No Yes Yes Yes Yes Yes Yes YesRate of intra-operative tumour soiling No Yes No * No No ? Yes YesProportion of stage II-III patients that received adjuvant No Yes Yes Yes Yes Yes No Not usedchemotherapyProportion of stage II-III patients that received adjuvantradiotherapy or chemoradiotherapy if no neoadjuvantNo Yes Yes Yes Yes Yes No Yes (forRT)therapyProportion of stage II-III patients that started adjuvantchemotherapy within 1 month after surgical resectionNo Yes No Yes No Yes No Not used
KCE Reports 81 PROCARE – phase 2 157Proportion of stage II-III pts treated with adjuvantchemo(radio)therapy, that received 5-FU based chemoBavaria Burgundy North NL SW SPAIN UK DK NNo ? No Yes No No No Not usedRate of acute grade 4 chemotherapy complications No No No No No No No Not usedRate of stage IV patients receiving chemotherapy Yes Yes Yes No Yes Yes No NoRate of acute grade 4 chemotherapy complications in No No No No No No No Nostage IV patientsRate of curatively treated patients that received aNo No No No Yes No Yes Nocolonoscopy within 1 year after treatmentRate of patients undergoing regular follow-up No No No Yes Yes No Yes NoLate grade 4 complications of radio(chemo)therapy No No No Yes Yes No No NoUse of the pathology report sheet No Yes No Yes Yes Yes Yes Yes(subsets)Quality of TME (according to Quirke) No No Yes Yes No No NoRate of good or moderate quality TME ? No No * No Yes No No NoDistal tumour-free margin after SSO ? No * Yes Yes Yes Yes Yes(subsets)Number of lymph nodes examined No Yes Yes Yes Yes Yes Yes Yes(subsets)(y)pCRM mentioned in the pathology report Yes No Yes Yes Yes Yes Yes(subsets)* only for studies 1994-1997 and 2001-2004
Page 1 and 2:
Assurance de qualitépour le cancer
Page 3 and 4:
Assurance de qualité pour lecancer
Page 5 and 6:
KCE Reports 81B Cancer rectal - pha
Page 7:
KCE Reports 81B Cancer rectal - pha
Page 10 and 11:
vi Cancer rectal - phase 2 KCE Repo
Page 12 and 13:
2 PROCARE - phase 2 KCE reports 81A
Page 14 and 15:
4 PROCARE - phase 2 KCE reports 811
Page 16 and 17:
6 PROCARE - phase 2 KCE reports 81F
Page 19 and 20:
KCE Reports 81 PROCARE - phase 2 92
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
KCE Reports 81 PROCARE - Phase 2 77
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116: KCE Reports 81 PROCARE - phase 2 10
Page 165: KCE Reports 81 PROCARE - phase 2 15
Page 169: KCE Reports 81 PROCARE - phase 2 15
Page 172 and 173: Dépôt légal : D/2008/10.273/39
Page 174 and 175: 35. Etude relative aux coûts poten
show all

Assurance de qualité pour le cancer rectal – phase 2 ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?